Home › Funds › Soleus Capital Management, L.P. › ERAS
Soleus Capital Management, L.P. position in ERAS
ERASCA INC · Health Care
Soleus Capital Management, L.P. reported holding 2,700,000 shares of ERAS (ERASCA INC) in its Q2 2026 13F filing — a position valued at US$49.5M, representing 1.70% of its reported portfolio and ranking #15 among its reported holdings. Soleus Capital Management, L.P. has disclosed ERAS holdings in 8 of the last 9 reported quarters, going back to Q2 2024.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Soleus Capital Management, L.P.'s ERAS position evolved
Soleus Capital Management, L.P. first disclosed a stake in ERAS in Q2 2024 at 2,162,162 shares (US$5.1M). The position peaked in Q2 2026 at 2,700,000 shares, worth US$49.5M. Across 8 filings, Soleus Capital Management, L.P. held the position steady without any share-count change. The most recent filing (Q2 2026) shows 2,700,000 shares valued at US$49.5M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2024 | 2.16M | $5.10M | New |
| Q3 2024 | 2.16M | $5.90M | Hold |
| Q4 2024 | 2.16M | $5.43M | Hold |
| Q1 2025 | 2.16M | $2.96M | Hold |
| Q2 2025 | 2.16M | $2.75M | Hold |
| Q3 2025 | 2.16M | $4.71M | Hold |
| Q4 2025 | 2.16M | $8.04M | Hold |
| Q2 2026 | 2.70M | $49.46M | New |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ERAS and 13F data
ERAS (ERASCA INC) is a Health Care company. 78 other funds we track also report a position in ERAS — the largest reported positions include Frazier Life Sciences Management, L.P. (US$457.5M), RTW INVESTMENTS, LP (US$328.8M), Venrock Adviser, LLC (US$327.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ERAS
- Frazier Life Sciences Management, L.P. 24.98M sh · $457.55M · Q2 2026
- RTW INVESTMENTS, LP 17.95M sh · $328.78M · Q2 2026
- Venrock Adviser, LLC 17.89M sh · $327.78M · Q2 2026
- Logos Global Management LP 12.15M sh · $222.59M · Q2 2026
- Siren, L.L.C. 11.40M sh · $208.81M · Q2 2026
- Paradigm Biocapital Advisors LP 9.55M sh · $174.96M · Q2 2026
- ARCH Venture Management, LLC 7.09M sh · $129.92M · Q2 2026
- Cormorant Asset Management, LP 6.00M sh · $109.92M · Q2 2026
- Affinity Asset Advisors, LLC 5.25M sh · $96.18M · Q2 2026
- Vivo Capital, LLC 4.13M sh · $75.61M · Q2 2026
- a16z Capital Management, L.L.C. 2.86M sh · $52.44M · Q2 2026
- SAMLYN CAPITAL, LLC 2.26M sh · $41.35M · Q2 2026
More on Soleus Capital Management, L.P.
FAQ
How long has Soleus Capital Management, L.P. held ERAS?
Soleus Capital Management, L.P. has disclosed ERAS holdings in 8 of the last 9 reported quarters, going back to Q2 2024.
What is Soleus Capital Management, L.P.'s current position in ERAS?
As of Q2 2026, Soleus Capital Management, L.P. holds 2.70M shares of ERAS (ERASCA INC), valued at $49.46M, representing 1.70% of its reported portfolio and ranking #15.
Has Soleus Capital Management, L.P. been buying or selling ERAS?
In the latest 13F filing (Q2 2026), Soleus Capital Management, L.P. newly opened its position in ERAS. The position peaked in Q2 2026 at 2.70M shares.
Which other funds hold ERAS?
Other major institutional holders of ERAS include Frazier Life Sciences Management, L.P., RTW INVESTMENTS, LP, Venrock Adviser, LLC, among 78 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.